Consistently, Sorafenib, the inhibitor of Raf, inhibited beta-catenin/TCF signaling in the tumorigenesis of HCC [9], suggesting that beta-catenin/TCF signaling could be regulated by Ras. Here, CTNNB1 is linked to hepatocellular carcinoma.